MONTREAL, Oct. 06, 2017 -- I-MED Pharma, Inc., a Canadian company specialized in dry eye diagnosis and management, announced today the appointment of AMWO Farma IVS as its exclusive distributor for the I-PEN® Tear Osmolarity System as well as the I-DROP® and I-LID ‘N LASH® dry eye products in Denmark, Sweden and Norway.
|
|||||
A photo accompanying this announcement is available at http://www.globenewswire.com/NewsRoom/AttachmentNg/a0c0fde2-b539-4851-adf7-8ed42648e5fb
Daniel Hofmann, President of I-MED commented, “We are pleased to have the opportunity to introduce our innovative products to Scandinavian eye care professionals and to give them new options for rapid, reliable diagnosis and effective, long lasting symptom relief for their dry patients.”
AMWO Farma CEO Claus Oldenburg said, “We are excited about our new relationship with I-MED Pharma and we look forward to introducing the I-PEN®, as well the Ocular Surface Disorder (OSD) line of products to ophthalmologists, optometrists and their patients. I-MED Pharma’s unique products offer a major leap forward in our efforts to improve the vision and quality of life of people with dry eye problems.”
I-MED Pharma is a privately held Canadian company, headquartered in Montreal, Quebec, servicing Canadian ophthalmologists, optometrists and the global eye care community. Established over twenty-five years ago, I-MED Pharma Inc. creates and distributes innovative medical, surgical and veterinary eye care products. It continually researches, develops and sources the most effective and advanced solutions to eye disorders like cataracts, corneal degenerations, dry eye, glaucoma and Meibomian gland disease.
I-MED Pharma is proud to have been at the forefront of treating Dry Eye Syndrome as a serious disease and investing heavily into education and developing effective dry eye products. Most recently, I-MED Pharma launched the world’s first hand-held in-vivo tear osmolarity test, the I-PEN® osmolarity device. I-MED Pharma’s ocular surface disease product range includes diagnostic tools, ocular hygiene, nutrition, dry eye drops and ocular occlusion devices.
For more information please email [email protected] or visit www.imedpharma.com.


Brazilian Oil Workers’ Strike Continues as Key Petrobras Union Rejects Proposal
Sanofi to Acquire Dynavax in $2.2 Billion Deal to Strengthen Vaccine Portfolio
Nvidia and Groq Strike Strategic AI Inference Licensing Deal
Lockheed Martin Secures $92.8M AEGIS Sustainment Contract from U.S. Navy
Star Entertainment Leadership Shake-Up Deepens as CFO and COO Exit Amid Ongoing Restructuring
Hyundai Recalls Over 51,000 Vehicles in the U.S. Due to Fire Risk From Trailer Wiring Issue
China’s LandSpace Takes Aim at SpaceX With Reusable Rocket Ambitions
Samsung Electronics Secures Annual U.S. Licence for China Chip Equipment Imports in 2026
Hanwha Signals Readiness to Build Nuclear-Powered Submarines at Philly Shipyard for U.S. Navy
TSMC Honors Japanese Chip Equipment Makers With 2025 Supplier Awards
BP’s Castrol Stake Sale Raises Debt Relief Hopes but Sparks Cash Flow Concerns
Citigroup to Exit Russia With Sale of AO Citibank to Renaissance Capital
Novo Nordisk and Eli Lilly Cut Obesity Drug Prices in China, Boosting Access to Wegovy and Mounjaro
Trump Administration Probes Corporate DEI Programs, Raising Questions for Google Stock
Australia’s Modern Gold Rush: Hobby Prospectors Flock to Victoria’s Golden Triangle
Applied Digital Stock Rises on AI Cloud Spinoff Plan and ChronoScale Launch 



